Introduction {#Sec1}
============

The prevalence of type 2 diabetes is increasing worldwide, but the rate of increase is particularly dramatic in non-Western countries that are experiencing rapid socioeconomic growth and urbanization, along with the associated changes in diet and life expectancy. Some 8.8% of adults worldwide are estimated to currently have diabetes, with type 2 diabetes constituting 95% of the burden \[[@CR1]\]. The prevalence of diabetes is currently highest in Saudi Arabia (17.6%), Egypt (16.7%), Bahrain (15.6%), UAE (14.6%), and Kuwait (14.3%) \[[@CR1]\]. By 2040, the prevalence of diabetes is forecast to increase such that it will affect 10% of the global population, placing growing pressure on healthcare resources and imposing a large economic burden \[[@CR1]\].

The aim of type 2 diabetes management is to minimize long-term complications, including micro- and macrovascular diseases, while avoiding any unwanted effects of treatment, such as hypoglycemia and weight gain. Current guidelines, supported by data from the UK Prospective Diabetes Study, recommend intensive blood glucose (BG) control to lower HbA1c below a target of 7.0% in most patients \[[@CR2]--[@CR4]\].

Type 2 diabetes is a progressive disease that requires continuous intensification and optimization of treatment to achieve and maintain HbA1c targets. Intensification strategies depend on an individual's characteristics, needs, and preferences, but most patients will eventually require insulin therapy due to the loss of beta-cell function \[[@CR2], [@CR5], [@CR6]\]. Basal insulin, such as long-acting insulin analogs or intermediate-acting neutral protamine Hagedorn (NPH) insulin, are commonly used as initial insulin therapies. When basal insulin fails to provide adequate glycemic control, the addition of rapid-acting mealtime insulin can be considered (basal--bolus), with progressive escalation in the number of injections \[[@CR2]\]. A premixed insulin regimen, providing both rapid-acting and intermediate-acting components in one formulation, can also be used to initiate or intensify insulin treatment \[[@CR3], [@CR7]\], and is widely used as the initial insulin therapy in African, Middle Eastern, and South-East Asian regions \[[@CR1], [@CR8]--[@CR10]\].

Biphasic insulin aspart 30 (BIAsp 30: NovoMix 30) is a premix of insulin aspart (IAsp) in which 30% is soluble short-acting IAsp and the remaining 70% is an intermediate-acting protamine cocrystallized IAsp \[[@CR11]\]. BIAsp 30 provides prandial insulin coverage while also offering adequate basal coverage, and can improve glycemic control in patients with type 2 diabetes previously inadequately controlled with basal insulins \[[@CR12]\].

Despite detailed guidelines on the use of insulin therapies, for many patients, achieving and maintaining HbA1c targets in routine clinical care represents a major challenge \[[@CR13]\]. Regional data indicate that only 16.4% of patients with type 2 diabetes in Egypt, 26.8% of patients in Morocco, 27.0% of patients in Saudi Arabia, and 32.2% of patients in Indonesia achieve HbA1c targets \<7% \[[@CR8], [@CR10], [@CR14], [@CR15]\]. There are many patient and physician barriers to insulin initiation and intensification, including a lack of education and awareness, and concerns about hypoglycemia and weight gain \[[@CR16]\]. Additional regional and cultural barriers exist in developing countries. In the Middle East, Africa, and South-East Asia in particular, there is often a gap between guideline-driven and actual diabetes care practices, and access to healthcare can be limited due to limited insurance coverage, low physician:population ratios, rural and inaccessible communities, and cost \[[@CR17]--[@CR19]\].

The titration of insulin doses over time is needed to achieve and maintain glycemic targets. Currently, many patients with type 2 diabetes have their insulin doses adjusted by physicians in a primary care setting \[[@CR20]\]. Dose adjustment is a time-consuming process, and additional barriers include the need for regular visits to clinics, the cost of glucose-testing strips, and the lack of education and experience of primary healthcare providers in titration.

Self-monitoring of BG and self-titration of insulin dose based on predefined algorithms (with clinical oversight) is well established in type 1 diabetes, and similar therapeutic self-management of various insulin regimens has been shown to be feasible in patients with type 2 diabetes \[[@CR6], [@CR21]--[@CR23]\]. A therapy protocol that is easily taught and self-titrated may allow more patients to initiate and optimize insulin therapy, thus reducing follow-up clinic visits and telephone calls. Premixed insulin analogs such as BIAsp 30 are simple and convenient to use, require fewer injections than basal--bolus treatment, and have relatively predictable time--action profiles that offer the potential for patients to effectively adjust their daily dose \[[@CR24], [@CR25]\].

The aim of this study was to confirm the efficacy of patient-driven titration of BIAsp 30 in terms of glycemic control, by comparing it to physician-driven titration of BIAsp 30, in patients with type 2 diabetes inadequately controlled with NPH insulin in North Africa, Asia, and the Middle East using a noninferiority approach.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients were enrolled at 18 sites across Egypt, Indonesia, Morocco, Saudi Arabia, and Vietnam between May 2012 and July 2015. Eligible patients were aged ≥18 years, had a diagnosis of type 2 diabetes for at least 12 months before screening, were currently being treated with NPH insulin (for at least 3 months) in combination with a stable total daily dose of at least 1500 mg or a maximum tolerated dose (minimum 1000 mg) of metformin for at least 2 months (with the exception of Indonesia, where the recommended daily dose was 750 mg) with or without additional oral antidiabetic drug (OAD) treatment, had HbA1c ≥7.0% (≥53.0 mmol/mol) and ≤10% (≤85.8 mmol/mol), and had a body mass index (BMI) of ≤40.0 kg/m^2^.

Key exclusion criteria included treatment with any thiazolidinedione, glucagon-like peptide-1 receptor agonists, and/or pramlintide within the 3 months before screening; treatment with more than 1 IU/kg NPH insulin daily; previous use of premixed or bolus insulins; more than one severe hypoglycemic episode during the previous 12 months; impaired kidney or hepatic function; or proliferative retinopathy or maculopathy requiring treatment.

Study Design {#Sec4}
------------

This was an open-label, randomized, two-armed, parallel-group, multicenter trial consisting of a 2-week screening period, a 4-week training period, and a maintenance period of 16 weeks. Patients were randomized 1:1 to receive patient-driven or physician-driven titration of BIAsp 30 twice daily (BID). All patients discontinued their previous NPH insulin and OADs, except for their pre-trial metformin. The dose and regimen of metformin was not changed throughout the trial period. Patients had a starting BIAsp 30 dose equivalent to their previous NPH insulin dose split into two equal doses, administered subcutaneously via FlexPen^®^ (Novo Nordisk, Bagsvaerd, Denmark) immediately before breakfast and immediately before dinner. Titration of BIAsp 30 in both arms was performed according to the titration protocol recommended by the BIAsp 30 summary of product characteristics \[[@CR26]\], and was based on self-measured plasma glucose (SMPG) values measured twice daily on three preceding days (Table [1](#Tab1){ref-type="table"}). Patients were provided with BG meters and plasma-calibrated BG test strips to record SMPG. All measurements performed with capillary blood were automatically calibrated to equivalent plasma glucose (PG) values. BIAsp 30 dose adjustments were made once a week in the training period and every second week in the maintenance period. Participants in the patient-driven arm had three clinic visits after randomization (weeks 4, 12, and 20) and telephone contact whenever deemed necessary. Participants in the physician-driven arm had six clinic visits (weeks 2, 4, 8, 12, 16, and 20) and telephone contact 1 week after the previous visit if one of the doses was changed, and at any other time if deemed necessary.Table 1Protocol for physician-driven and patient-driven titration of BIAsp 30SMPG valueBIAsp 30 dose adjustment (U)^a^mmol/Lmg/dL\<4.4\<80−24.4--6.180--11006.2--7.8111--140+27.9--10141--180+4\>10\>180+6BIAsp dose adjustment was based on the lowest SMPG measured before breakfast and before dinner in the preceding 3 days. The lowest SMPG value before breakfast was used to adjust the following dinner dose and the lowest SMPG value before dinner was used to adjust the following breakfast dose*SMPG* self-measured plasma glucose, *U* units^a^No increase in dose if hypoglycemia \[≤3.9 mmol/L (70 mg/dL)\] occurred in the preceding 3 days

The titration algorithms, efficacy and safety assessments, and statistical analysis methods used in this study were the same as those described for another study in a previous publication \[[@CR27]\].

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent to be included in the study was obtained from all patients. The study protocol was approved by the Ministry of Health of Egypt, as well as by the Ethics Committee of the Faculty of Medicine at Alexandria University, Alexandria, Egypt. The ClinicalTrials.gov clinical trial identifier number is NCT01589653.

Efficacy and Safety Assessments {#Sec5}
-------------------------------

The primary endpoint was change in HbA1c from baseline to week 20. Secondary supportive endpoints included: proportion of patients achieving the American Diabetes Association (ADA) target of HbA1c \<7.0% and the HbA1c target of ≤6.5% after 20 weeks of treatment with and without severe and minor hypoglycemic episodes during the last 12 weeks of the trial; change in fasting plasma glucose (FPG) levels from baseline; a 7-point SMPG profile (PG values measured before and 90 min after the start of breakfast, lunch, and main evening meal, and prior to bedtime); time to PG target using 2-point SMPG profile \[first time PG values before breakfast and before dinner both reached 4.4--6.1 mmol/L (80--110 mg/dL)\]; patient satisfaction assessed by Treatment-Related Impact Measures for Diabetes (TRIM-D) scores \[[@CR28]\]; and assessment of healthcare resource utilization (clinic visits, telephone calls to the clinic, and BG strips).

Safety and tolerability were assessed in terms of treatment-emergent hypoglycemic episodes and treatment-emergent adverse events (AEs). A hypoglycemic episode was defined as treatment-emergent if the onset occurred after the first administration of BIAsp 30 and no later than the last day of administration within the trial. An AE was defined as treatment-emergent if the onset occurred on or after the first day of BIAsp 30 administration and no later than 7 days after the last day.

Minor hypoglycemic episodes were defined as an episode with symptoms consistent with hypoglycemia \[as confirmed by PG \<3.1 mmol/L (\<56 mg/dL) or full BG value \<2.8 mmol/L (\<50 mg/dL)\] which was handled by the patient himself/herself, or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full BG value \<2.8 mmol/L (\<50 mg/dL). Severe hypoglycemia was defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia was defined as an episode during which typical symptoms of hypoglycemia are accompanied by a measured PG concentration of ≤3.9 mmol/L (≤70 mg/dL). Asymptomatic hypoglycemia was defined as an episode not accompanied by typical symptoms of hypoglycemia, but with a measured PG concentration of ≤3.9 mmol/L (≤70 mg/dL). Probable symptomatic hypoglycemia was defined as an episode during which symptoms of hypoglycemia are not accompanied by a PG determination \[but the episode was presumably caused by a PG concentration of ≤3.9 mmol/L (≤70 mg/dL)\]. Relative hypoglycemia was defined as an episode during which the person with diabetes reports any of the typical symptoms of hypoglycemia and interprets those as indicative of hypoglycemia, but with a measured PG concentration of \>3.9 mmol/L (\>70 mg/dL) \[[@CR29]\]. An episode with an onset time between 00:00 and 05:59 (inclusive of both) was defined as a nocturnal episode.

Statistical Analysis {#Sec6}
--------------------

The analysis sets were defined in accordance with ICH-E9 guidance \[[@CR30]\]. The full analysis set (FAS) included all randomized patients, and the statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and patients contributed to the evaluation "as randomized." Missing values were imputed using the last observation carried forward (LOCF) method. The per protocol (PP) analysis set included all patients who were exposed to patient-driven titration or physician-driven titration for more than 12 weeks and had a valid assessment for deriving the primary endpoint without any major protocol violations that could affect the primary endpoint. The safety analysis set (SAS) included all patients who received at least one dose of BIAsp 30. Patients in the PP set and the SAS contributed to the evaluation "as treated."

Sample size calculation was determined using a*t* statistic under the assumption of a one-sided test of size 2.5% and a zero mean treatment difference in HbA1c between treatment arms (primary endpoint). The minimum sample size required to meet the primary endpoint with at least 80% power using the PP analysis set was 162 with an assumed standard deviation (SD) of 0.9%. Based on an expected exclusion of 10%, a randomization of 180 patients was planned. Despite the recruitment period being extended, the study was prematurely terminated as the required numbers of eligible patients were not available.

The primary endpoint of the study was change in HbA1c from baseline to week 20, analyzed using a normal linear regression model with treatment, stratum (metformin monotherapy versus metformin + additional OAD therapy), and country as factors, and baseline HbA1c as covariate. Patient-driven titration was considered noninferior to physician-driven titration if the upper boundary of the two-sided 95% confidence interval (CI) for the difference in change from baseline in HbA1c after 20 weeks of treatment between titration arms was ≤0.4%.

Sensitivity analyses were performed with all available HbA1c measurements taken post-randomization at scheduled measurement times using a mixed model for repeated measurements (MMRM). The model included treatment, time, treatment-by-time interaction, baseline HbA1c, stratum, and region as fixed factors, and subject as a random effect. Based on this model, treatment differences were estimated after 4, 12, and 20 weeks.

The proportions of patients achieving the target of HbA1c \<7.0% and ≤6.5% after 20 weeks of treatment with and without hypoglycemic episodes (severe and documented symptomatic episodes, and severe and minor episodes) were analyzed separately based on a logistic regression model using treatment, strata, and country as factors and baseline HbA1c as covariate.

Change from baseline in FPG after 20 weeks of treatment was analyzed using a normal linear regression model using treatment, stratum, and country as factors, and baseline FPG as covariate.

A mixed-effect model was fitted to the 7-point SMPG profile data at week 20. The model included treatment, time, interaction between treatment and time, stratum, and country as fixed factors, and patient as a random effect.

The prandial PG increment for each meal was derived from the 7-point SMPG profile as the difference between PG values available before a meal and 90 min after a meal. Prandial PG increments for each meal were analyzed using a normal linear regression model, with treatment, stratum, and country as factors, and the corresponding baseline value as covariate.

Time to reach PG target was assessed using the 2-point SMPG profile. The event-free survival endpoint was analyzed using a Cox proportional hazards model including treatment, stratum, and country as factors. Subjects who were lost to follow-up without meeting the target and subjects who never met the target during treatment were censored at the last day of treatment.

The PRO questionnaire included TRIM-D, which was scored as an overall score, as well as five subscale scores. After recording the 20 required items, the scores were transformed to a 0--100 scale, with higher scores indicating a better health state than lower scores. Each of the subscale scores and the overall score were analyzed separately using a normal linear regression model including treatment, stratum, and country as factors, and the corresponding baseline score as covariate.

The number of hypoglycemic episodes was analyzed using a negative binomial regression model with a log-link function, offset by the logarithm of the time period in which a hypoglycemic episode was considered treatment-emergent. The model included treatment, stratum, and country as factors.

Change from baseline in body weight after 20 weeks of treatment was analyzed using a normal linear regression model, with treatment, stratum, and country as factors, and baseline weight as covariate.

Results {#Sec7}
=======

Patients and Physicians {#Sec8}
-----------------------

Of the 280 patients screened, 155 were randomized, among whom 88.4% completed the study (Fig. [1](#Fig1){ref-type="fig"}). There were 125 screening failures; 84 patients did not meet the HbA1c inclusion criteria (≥7% and ≤10%) and 26 patients were lost after a study site was discontinued. The dropout rates were 9.2% (seven of 76 patients) and 13.9% (11 of 79 patients), respectively, for the patient-driven and physician-driven arms. Baseline characteristics were comparable across titration arms (Table [2](#Tab2){ref-type="table"}). Overall, mean age was 54.7 years, diabetes duration was 9.5 years, HbA1c was 8.6%, and BMI was 29.0 kg/m^2^, with males comprising 25.2% of the study enrollment. At screening, 16.1% of patients had diabetic neuropathy, 5.2% had macroangiopathy, 3.2% had diabetic retinopathy, and 3.2% had diabetic nephropathy.Fig. 1Patient enrollment, randomization, and analysis. *PP* per protocol Table 2Demographics and baseline characteristics of randomized patients switching from an NPH insulin regimen to BIAsp 30 BIDPatient-driven titration\
(*n* = 76)Physician-driven titration\
(*n* = 79)Age, years54.4 (10.2)54.9 (9.8)Gender M/F, *n* (%)16/60 (21.1/78.9)23/56 (29.1/70.9)Country Egypt, *n* (%)18 (23.7)22 (27.8) Indonesia, *n* (%)14 (18.4)18 (22.8) Morocco, *n* (%)21 (27.6)22 (27.8) Saudi Arabia, *n* (%)10 (13.2)7 (8.9) Vietnam, *n* (%)13 (17.1)10 (12.7)BMI, kg/m^2^29.2 (4.9)28.9 (4.9)Duration of diabetes, years8.7 (5.1)10.3 (6.5)HbA1c, %8.5 (0.88)8.7 (0.78)FPG mmol/L8.7 (3.3)8.2 (3.0) mg/dL156.8 (59.0)148.5 (54.2)Stratum, *n* (%) Metformin32 (42.1)35 (44.3) Metformin + additional OADs44 (57.9)44 (55.7)Diabetic nephropathy, *n* (%)5 (6.6)0 (0.0)Diabetic neuropathy, *n* (%)10 (13.2)15 (19.0)Diabetic retinopathy, *n* (%)2 (2.6)3 (3.8)Macroangiopathy, *n* (%)4 (5.3)4 (5.1)Data are mean (SD) unless stated otherwise*BID* twice daily, *BMI* body mass index, *FPG* fasting plasma glucose, *M/F* male/female, *NPH* neutral protamine Hagedorn, *OAD* oral antidiabetic drug

In the physician-driven arm, dose adjustment was performed by general physicians (*n* = 2), specialists (*n* = 21), and internists (*n* = 15).

Efficacy {#Sec9}
--------

Observed mean HbA1c decreased throughout the study in both titration arms (Fig. [2](#Fig2){ref-type="fig"}a). The reduction in HbA1c for the FAS was numerically higher in the first 4 weeks of treatment in the physician-driven than in the patient-driven arm.Fig. 2**a** Mean (±SE) HbA~1c~ levels (LOCF) over time; **b** observed proportions of patients who had HbA~1c~ levels (LOCF) of \<7% or ≤6.5% at week 20; **c** observed proportions of patients reaching HbA~1c~ targets (LOCF) without severe and minor hypoglycemic episodes at week 20. Data from FAS. \*Estimated odds ratio (95% CI) for patient-driven versus physician-driven titration. Logistic regression with treatment, stratum, region, and baseline HbA1c as explanatory variables. Minor hypoglycemic episodes were defined as episodes with symptoms consistent with hypoglycemia as confirmed by PG \<3.1 mmol/L (\<56 mg/dL) or full BG value \<2.8 mmol/L (\<50 mg/dL) and handled by the patient himself/herself, or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full BG value \<2.8 mmol/L (\<50 mg/dL). Severe hypoglycemia was defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. *BG* blood glucose, *CI* confidence interval, *FAS* full analysis set, *LOCF* last observation carried forward, *PG* plasma glucose, *SE* standard error

The estimated mean \[standard error (SE)\] reduction in HbA1c from baseline to week 20 was −1.27 (0.11)% and −1.04 (0.11)% in the patient-driven and physician-driven arms, respectively, for the FAS, with an estimated treatment difference (ETD; patient-driven minus physician-driven) of −0.23% (95% CI −0.54; 0.08). Noninferiority of patient-driven compared to physician-driven titration with respect to reduction in HbA1c was confirmed for the FAS, as the upper bound of the two-sided 95% CI was ≤0.4%. Repeating the primary analysis on the PP analysis set gave similar results. The MMRM sensitivity analysis supported the findings from the primary analysis, with an ETD of −0.15% (95% CI −0.49; 0.19) after 20 weeks of treatment.

More patients reached the HbA1c target levels of \<7.0% (\<53.0 mmol/mol) and ≤6.5% (≤47.5 mmol/mol) in the patient-driven compared to the physician-driven titration arm at week 20 (Fig. [2](#Fig2){ref-type="fig"}b). Furthermore, there were more patients who reached target HbA1c levels of \<7.0% (\<53.0 mmol/mol) or ≤6.5% (≤7.5 mmol/mol) without severe or minor hypoglycemic episodes in the patient-driven than in the physician-driven arm at week 20 (Fig. [2](#Fig2){ref-type="fig"}c).

FPG decreased in both titration arms throughout the study (Fig. [3](#Fig3){ref-type="fig"}a). The estimated mean (SE) FPG change from baseline to week 20 was −0.95 (0.28); −17.04 (5.10) mg/dL in the patient-driven and −0.67 (0.28); −12.05 (5.10) mg/dL in the physician-driven arm, with an ETD between titration arms of −0.28 mmol/L (95% CI −1.07; 0.52); −4.99 mg/dL (95% CI −19.32; 9.34).Fig. 3**a** Mean change from baseline FPG (LOCF); **b** 7-point SMPG profiles from baseline and after 20 weeks of treatment (EOT); **c** total daily insulin dose. Data from FAS. *EOT* end of trial, *FPG* fasting plasma glucose, *LOCF* last observation carried forward, *SMPG* self-measured plasma glucose

Treatment with BIAsp 30 decreased the 7-point SMPG profile measurements from baseline in both the patient- and the physician-driven arms \[ETD in overall profile: 0.2 mmol/L (95% Cl −0.3; 0.7); 4.3 mg/dL (95% CI −4.72;13.37)\] (Fig. [3](#Fig3){ref-type="fig"}b). After 20 weeks of treatment, the observed mean prandial PG increments were similar for the two arms at breakfast, lunch, and dinner. The observed mean increment across all meals was 1.8 mmol/L (33.3 mg/dL) in the patient-driven arm and 2.0 mmol/L (35.1 mg/dL) in the physician-driven arm.

By the end of the study, 57.9% of the patients in the patient-driven arm and 70.9% of the patients in the physician-driven arm had reached the 2-point SMPG target. Time to first reach the 2-point SMPG target was also similar in both arms \[14.4 weeks (95% CI 12.3; 19.9) for the patient-driven arm and 13.9 weeks (95% CI 10.1; 14.1) for the physician-driven arm\].

Patient-Reported Outcomes and Healthcare Utilization {#Sec10}
----------------------------------------------------

Total and individual domain TRIM-D questionnaire scores in the titration arms were similar. The total mean TRIM-D score increased from 66.9 to 75.1 out of 100 in the patient-driven arm and from 65.9 to 72.5 out of 100 in the physician-driven arm.

In accordance with the trial design, clinic visits to healthcare professionals were less frequent in the patient-driven arm \[mean (SD) 4.8 (0.65) visits/patient\] than in the physician-driven arm \[7.5 (1.42) visits/patient\], and the mean (SD) total number of BG strips used per patient during the 20-week study was moderately higher in the patient-driven arm \[37.5 (15.22) per patient\] compared with the physician-driven arm \[31.3 (20.33) per patient\].

BIAsp Dose {#Sec11}
----------

The majority of subjects included in the SAS in the patient-driven arm (84.2%) and physician-driven arm (75.9%) were exposed to BIAsp 30 for \>20 weeks, with no apparent differences in exposure time between arms (27.45 and 28.13 subject-years in the patient-driven and physician-driven arms, respectively). The mean total daily dose of BIAsp 30 was numerically higher in the patient- versus the physician-driven arm throughout the study. After 20 weeks of treatment, the mean (SD) total daily insulin dose in the FAS was 0.7 (0.31) U/kg in the patient-driven arm and 0.6 (0.23) U/kg in the physician-driven arm (Fig. [3](#Fig3){ref-type="fig"}c).

Safety {#Sec12}
------

Of the 154 participants included in the SAS, 77 experienced one or more treatment-emergent hypoglycemic episodes during the 20 weeks of treatment (Table [3](#Tab3){ref-type="table"}). The rate of hypoglycemic episodes was 608.4 versus 789.2 per 100 patient-years of exposure in the patient- and physician-driven arms, respectively (Table [3](#Tab3){ref-type="table"}). There were only three episodes of severe hypoglycemia: two episodes reported by one participant in the patient-driven arm and one episode in the physician-driven arm. The estimated rate ratio (RR) between patient-driven and physician-driven titration was 0.74 (95% CI 0.44; 1.23) for overall ADA-classified treatment-emergent hypoglycemic episodes, 0.66 (95% CI 0.32; 1.34) for severe or minor episodes, and 1.07 (95% CI 0.46; 2.49) and 0.82 (95% CI 0.27; 2.53) for nocturnal and severe or minor nocturnal episodes, respectively.Table 3Summary of treatment-emergent hypoglycemic episodes by ADA classificationADA classificationPatient-driven titration\
(*n* = 76)Physician-driven titration\
(*n* = 79)All36 (47.4) \[167\] {608.4}41 (52.6) \[222\] {789.2}Severe1 (1.3) \[2\] {7.3}1 (1.3) \[1\] {3.6}Documented symptomatic23 (30.3) \[90\] {327.9}31 (39.7) \[120\] {426.6}Relative7 (9.2) \[9\] {32.8}14 (17.9) \[18\] {64}Probable symptomatic7 (9.2) \[18\] {65.6}5 (6.4) \[9\] {32.0}Asymptomatic12 (15.8) \[23\] {83.8}13 (16.7) \[26\] {92.4}Unclassifiable9 (11.8) \[25\] {91.1}16 (20.5) \[48\] {170.6}Data are shown as *n* (%) \[*E*\] {rate}*%* percentage of subjects, *ADA* American Diabetes Association, *E* number of episodes, *n* number of subjects, *rate* rate per 100 patient-years of exposure

Patients gained weight in both titration arms. The mean absolute change in body weight (SD) was 1.4 (3.5) kg in the patient-driven arm and 1.9 (4.1) kg in the physician-driven arm \[ETD −0.26 kg (95% CI −1.45; 0.93)\].

The overall rate of treatment-emergent AEs was numerically higher in the patient-driven than in the physician-driven arm (324.2 vs. 302.2 events per 100 patient-years of exposure) (Table [4](#Tab4){ref-type="table"}). Five serious AEs were reported in the physician-driven arm and all were judged as "unlikely to be related to trial product" by an investigator.Table 4Summary of treatment-emergent AEsPatient-driven titration\
(*n* = 76)Physician-driven titration\
(*n* = 79)All28 (36.8) \[89\] {324.2}37 (47.4) \[85\] {302.2}Serious0 (0.0) \[0\] {0}5 (6.4) \[5\] {17.8}Severe2 (2.6) \[2\] {7.3}4 (5.1) \[4\] {14.2}Moderate14 (18.4) \[20\] {72.9}12 (15.4) \[15\] {53.3}Mild22 (28.9) \[67\] {244.1}31 (39.7) \[66\] {234.6}Possibly related to trial product0 (0.0) \[0\] {0}0 (0.0) \[0\] {0}Probably related to trial product2 (2.6) \[2\] {7.3}1 (1.3) \[2\] {7.1}Unlikely to be related to trial product28 (36.8) \[87\] {316.9}37 (47.4) \[83\] {295.1}Data are shown as *n* (%) \[*E*\] {rate}*%* percentage of subjects, *ADA* American Diabetes Association, *AE* adverse event, *E* number of episodes, *n* number of subjects, *rate* rates per 100 patient-years of exposure

No safety issues were observed in the assessment of vital signs, physical examinations, or laboratory tests.

Discussion {#Sec13}
==========

This multicenter, randomized controlled trial (RCT) showed that, after switching from NPH insulin to BIAsp 30, patient-driven titration was noninferior to physician-driven titration with respect to change in HbA1c from baseline after 20 weeks of treatment. It is important to note that a key limitation of this study was the low number of randomized patients. Recruitment of patients was prematurely terminated due to the small number of eligible patients receiving treatment with NPH insulin at the study sites. However, the results of this study are in line with previous RCTs that have reported self-titration of insulin to be effective in improving glycemic control in patients with type 2 diabetes \[[@CR6], [@CR21]--[@CR23]\]. For example, the ATLAS study reported that patient-driven insulin glargine titration was noninferior to physician-driven titration with near-target glycemic control in Asian patients with type 2 diabetes uncontrolled with oral glucose-lowering drugs \[[@CR31], [@CR32]\].

In this study, the reduction in HbA1c was numerically greater in the first 4 weeks of treatment in the physician-driven than in the patient-driven arm. However, after 12 weeks, the reduction in HbA1c was comparable between the arms. In addition, the uptitration of insulin dose was more aggressive in the physician-driven arm in the first 4 weeks of the study. This observation indicates that, initially, patients were learning how to titrate using the algorithm and, when comfortable, were able to achieve expected glycemic control. Other outcomes of efficacy (FPG, PG increments, and SMPG profiles) appear to be comparable between titration arms, further suggesting that patient-driven titration can be as successful as physician-driven titration. Patient satisfaction, as measured by TRIM-D scores, was also similar in both titration arms.

The numerically greater reduction in HbA1c from baseline to week 20 in the patient-driven arm may be due to the more aggressive titration of the insulin dose by patients compared to that by physicians in the maintenance period of the study. However, the higher end of the treatment insulin dose and the reduction in HbA1c were not achieved at the expense of increased hypoglycemic episodes, indicating that, with adequate training, patient-driven titration of BIAsp 30 does not raise additional safety concerns.

This is the first RCT to demonstrate that patient-driven titration was as effective as physician-driven titration in achieving recommended HbA1c targets in patients switching from NPH insulin to BIAsp 30 in non-Western countries. A small real-world study in a Dutch clinical practice has shown that patients with type 2 diabetes who switch from previous insulin regimens, including NPH insulin, to BIAsp 30 and are willing to self-titrate can improve glycemic control \[[@CR33]\].

Previous RCTs have demonstrated noninferiority of patient-driven versus physician-drive titration of BIAsp 30 but in patient populations different from the current study. The INITIATEplus trial enrolled insulin-naïve patients with type 2 diabetes poorly controlled on OADs \[[@CR20]\], and another study enrolled Chinese patients switching from premixed/self‐mixed human insulin to BIAsp 30 \[[@CR34]\]. In contrast, the SimpleMix trial, conducted in Argentina, China, India, Poland, and the UK in patients with type 2 diabetes inadequately controlled on basal insulin analogs, could not confirm the noninferiority of patient-driven versus investigator-driven titration of BIAsp \[[@CR27]\].

In the current study, glycemic control was improved after switching from NPH insulin to BIAsp 30 in both arms, highlighting the value of insulin intensification in patients with type 2 diabetes. Modern insulin analogs have the advantage of a lower risk of hypoglycemia and weight gain, as well as more predictable insulin action, compared with traditional human insulin formulations \[[@CR35]\]. Additionally, premixed insulin analogs offer the benefit of being simple to use, with fewer injections, and being similarly efficacious and safe to a basal--bolus regimen \[[@CR36], [@CR37]\].

With increasing numbers of patients with diabetes and limited healthcare resources, especially in non-Western countries, there will be a greater need for patients to self-manage their disease. In this study, fewer clinic visits were made per person in the patient-driven than in the physician-driven arm, suggesting that self-titration reduces healthcare utilization. In a similar trial in a Chinese population, patient-driven titration of BIAsp 30 was associated with less healthcare utilization and lower direct and nondirect costs compared to physician-driven titration, without compromising glycemic control \[[@CR38]\].

Key issues when deciding whether the patient or a physician should titrate insulin and in the success of patient-driven titration are the patients' ability and motivation to manage their disease. This is influenced by factors such as age, socioeconomic status, health literacy and numeracy, and cultural aspects of healthcare in different countries. Poor health literacy and numeracy are associated with a low level of disease knowledge, fewer self-management behaviors, difficulty understanding titration instructions, and poorer diabetes outcomes \[[@CR6]\]. Disease empowerment and education play significant roles in improving self-care behavior, quality of life, and outcomes in diabetes patients \[[@CR39], [@CR40]\]. This study demonstrates that, after a 4-week training period, patients in non-Western countries are able to effectively and safely self-titrate BIAsp 30 using a predefined algorithm.

Conclusions {#Sec14}
===========

This was the first randomized study to demonstrate that patient-driven titration of BIAsp 30 BID can be at least as effective and safe as physician-driven titration of BIAsp 30 BID in non-Western patients with type 2 diabetes that is no longer controlled with NPH insulin.
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